Financial Data and Key Metrics Changes - In Q1 2025, Novanta reported revenue of $233 million, reflecting organic growth of 2% and reported growth of 1% year over year [6][21] - Adjusted gross margins were 46%, consistent with expectations, while adjusted EBITDA was $50 million, showing a 1% increase year over year [24][6] - Free cash flow reached $32 million, exceeding expectations and demonstrating strong cash conversion capabilities [24][6] Business Line Data and Key Metrics Changes - Medical market sales accounted for 55% of total sales, while advanced industrial markets made up 45% [14] - The Automation Enabling Technologies segment saw sales grow by 5% year over year, driven by strength in robotics and automation [27] - The Medical Solutions segment experienced a revenue decline of 3% year over year, primarily due to a drop in the precision medicine business unit [28] Market Data and Key Metrics Changes - Sales to healthcare markets grew at a high single-digit rate, particularly in the advanced surgery business [9][10] - The precision medicine business unit faced disruptions from NIH funding cuts and tariffs, impacting overall sales [29][30] - Design wins in the automation enabling technology segment grew by strong double digits year over year, indicating robust demand despite market turbulence [16][27] Company Strategy and Development Direction - Novanta's strategy focuses on markets with long-term secular tailwinds, such as precision robotics and advanced minimally invasive surgery [7][8] - The company aims to achieve $50 million in incremental new product revenue in 2025, driven by new product launches [10][21] - The acquisition of Keyon is part of Novanta's strategy to expand into intelligent embedded software solutions [19][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the current macroeconomic environment as uncertain and volatile, similar to the early COVID pandemic days [11] - The company is confident in its ability to navigate these challenges, citing enhanced operational scalability and resilience [12][22] - Despite short-term uncertainties, management remains optimistic about long-term growth opportunities in high-growth markets [21][40] Other Important Information - Novanta's gross debt was $392 million, with a gross leverage ratio of 1.9 times, providing capacity for further acquisitions [25] - The company repurchased approximately $6 million worth of common shares in Q1 2025 [25][26] - The vitality index for new products reached nearly 20% of total sales, indicating strong growth potential [17] Q&A Session Summary Question: Can you provide insights on the Keyon acquisition and its revenue contribution? - The upfront payment for Keyon was around $66 million, with expectations for it to be slightly accretive to earnings per share in the first year [51][52] Question: What are the sources of the $20 million in annual cost savings? - The $20 million in savings is primarily from deferrals of investments and prioritization of actions to mitigate tariff impacts [55][56] Question: How is Novanta addressing the impact of tariffs on its supply chain? - The company has implemented a tariff response playbook, which includes sourcing from second vendors and regionalizing manufacturing to mitigate costs [33][80] Question: What is the outlook for revenue in Q2 2025? - Novanta expects Q2 revenue in the range of $230 million to $240 million, trending towards the higher end of this range [41][61] Question: How much of Novanta's revenue is tied to NIH funding? - The precision medicine business unit is sensitive to NIH funding cuts, which have impacted revenue, but specific revenue percentages are difficult to quantify [70][73]